Open AccessEmpagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial
Author(s) -
David Fitchett,
Silvio E. Inzucchi,
Christopher P. Can,
Darren K. McGuire,
Benjamin M. Scirica,
Odd Erik Johansen,
Steven Sambevski,
Stefan Kaspers,
Egon Pfarr,
Jyothis T. George,
Bernard Zinman
Publication year - 2019
Publication title -
circulation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 7.795
H-Index - 607
eISSN - 1524-4539
pISSN - 0009-7322
DOI - 10.1161/circulationaha.118.037778
Subject(s) - medicine , mace , empagliflozin , timi , myocardial infarction , cardiology , heart failure , diabetes mellitus , placebo , stroke (engine) , hazard ratio , type 2 diabetes , conventional pci , confidence interval , mechanical engineering , alternative medicine , pathology , engineering , endocrinology
In the EMPA-REG OUTCOME trial (BI 10773 [Empagliflozin] Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients) in patients with type 2 diabetes mellitus and atherosclerotic cardiovascular disease, in comparison with placebo, empagliflozin reduced the risks of 3-point major adverse cardiovascular events (3-point MACE), cardiovascular and all-cause death, and hospitalization for heart failure. We investigated whether these effects varied across the spectrum of baseline cardiovascular risk.